MAP2K7 and pancreatic neoplasm: The efficacy of this autophagic inhibitor has also been investigated, in a phase I/II clinical trial, in combination with binimetinib (MEK inhibitor), ulixertinib (ERK inhibitor) and gemcitabine, in pancreatic cancer and gastrointestinal adenocarcinomas [145,146].